All News

Md Yuzaiful Md Yusof Tweet
Yuz6Yusof
Potential new player on the block, B-cell associated cytokine IL-40 in #Sjogren. Dr Rizzo showed ⬆️IL40 expression in salivary gland biopsy & bloods in pSS and pSS-associated lymphoma. Future work will clarify the exact role of IL-40 as a tx target #EULAR2021 #POS0177 @RheumNow https://t.co/uXAYAlkdtD
Meral K. El Ramahi, MD Tweet
MeralElRamahiMD

⭐️Deucravacitnib = oral TYK2i w/ downstream inhibitory effects on IL23, IL12 & type I IFN pathways ⭐️Recent studies (POETYK PSO-1/2) show that it outperforms Otezla per PASI75 ⭐️OP0227 shows it is also efficacious for active PsA vs PBO w/ no serious AEs #EULAR2021 @Rheumnow https://t.co/qA1NsLzQsF

Md Yuzaiful Md Yusof Tweet
Yuz6Yusof
Does #baricitinib affect B-cell activity in #SLE?Dr Dorner reported in patients with dsDNA ab+ve (=>30iU/mL), Bari 4mg reduced dsDNA,anti-Sm, cardiolipin and IgG at Wk24 vs placebo. In pts who dsDNA normalised, their SRI-4 was no different vs dsDNA+ #EULAR2021 #POS0686 @RheumNow https://t.co/pmNWEE9hqg
Meral K. El Ramahi, MD Tweet
MeralElRamahiMD
OP0227: Efficacy of Deucravactinib for PsA? ⭐️Deucrav = TYK2i. ⭐️Dr. Mease et al show MDA by wk16 + stat. signif improv in ACR20/50/70, enthes, & dactyl w/ deucrav vs PBO in pts w/ active PsA. ⭐️Incl crit: failed at least 1 csDMARD/NSAID/GC & up to 1 TNFi #EULAR2021 @Rheumnow https://t.co/1jjsZIODFV
Md Yuzaiful Md Yusof Tweet
Yuz6Yusof
#SLE and #Sjogren: is there a path for these to converge? Dr Martin-Guttierez used #MachineLearning to analyse blood & identified 2 endotypes. Both had different trajectory in disease activity & damage. May be useful to stratify appropriate therapy #EULAR2021 #POS0174 @RheumNow https://t.co/R4NMDJYVbY
Richard Conway Tweet
RichardPAConway
Dr Eder reports population-based, matched cohort study 3 million people. IMID associated ⬆️ hospitalisation in COVID-19. OR 1.23, 95% CI 1.10, 1.37 @RheumNow #EULAR2021 Abstr#OP0285 https://t.co/KDK5j1Gg0X
Dr. Rachel Tate Tweet
uptoTate
Dr. Laura Coates discusses "what is fatigue" based on clinical outcome and disease activity measures in PsA. Three main groups stood out in predicting fatigue in these patients: level of inflammation, chronic pain, and chronicity of PsA disease. #EULAR2021 @RheumNow https://t.co/pFYRb1X7pT
Dr. John Cush Tweet
RheumNow

RheumNow’s expanded coverage of the #EULAR2021 Annual meeting is sponsored in part by Novartis, Bristol Myers Squibb, and Janssen. All content chosen by RheumNow and its faculty.

Janet Pope Tweet
Janetbirdope
JAKi to #JAKi cycling is common in #rheumatoidarthritis Rx. Opal registry >53000 pts, 1/4 treated with JAKi (4000) & 44% new starts were Jaki. JAKi to JAKi cycling was >40%! POS0223 #EULAR2021 ⁦@RheumNow⁩ https://t.co/XV7wVJsE9c
Dr. Rachel Tate Tweet
uptoTate
"What we really need in SpA/PsA is personalized medicine in order to choose the best drug MOA for our patients." Dr. Laura Coates addressing paradox of choice in treatment options. I remain hopeful for better biomarkers for future precision medicine approach. #EULAR2021 @RheumNow https://t.co/nIDksfTe7h
Richard Conway Tweet
RichardPAConway
Dr Hellgren on pregnancy outcomes in RA 📈disease activity assoc preterm birth and small gestational age. Low disease activity = no increased risk compared controls @RheumNow #EULAR2021 Abstr#OP0210 https://t.co/L26xWhIFv6
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×